 Oligonucleotides, Antisense
"Oligonucleotides, Antisense" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Short fragments of DNA or RNA that are used to alter the function of target RNAs or DNAs to which they hybridize.
| Descriptor ID |
D016376
|
| MeSH Number(s) |
D13.150.480 D13.444.600.150.640 D13.695.578.424.480 D27.720.470.530.600.150.640
|
| Concept/Terms |
Oligonucleotides, Antisense- Oligonucleotides, Antisense
- Antisense Oligonucleotides
- Anti-Sense Oligonucleotides
- Anti Sense Oligonucleotides
- Oligonucleotides, Anti-Sense
|
Below are MeSH descriptors whose meaning is more general than "Oligonucleotides, Antisense".
Below are MeSH descriptors whose meaning is more specific than "Oligonucleotides, Antisense".
This graph shows the total number of publications written about "Oligonucleotides, Antisense" by people in this website by year, and whether "Oligonucleotides, Antisense" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 1 | 1 | 2 | | 1997 | 2 | 1 | 3 | | 1998 | 0 | 2 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 6 | 7 | | 2004 | 1 | 6 | 7 | | 2005 | 0 | 2 | 2 | | 2006 | 1 | 2 | 3 | | 2007 | 0 | 3 | 3 | | 2008 | 1 | 5 | 6 | | 2009 | 3 | 3 | 6 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 4 | 4 | | 2012 | 0 | 1 | 1 | | 2014 | 5 | 2 | 7 | | 2015 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 | | 2021 | 1 | 3 | 4 | | 2022 | 0 | 2 | 2 | | 2023 | 1 | 0 | 1 | | 2024 | 2 | 1 | 3 | | 2025 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligonucleotides, Antisense" by people in Profiles.
-
Cheerie D, Meserve MM, Beijer D, Kaiwar C, Newton L, Taylor Tavares AL, Verran AS, Sherrill E, Leonard S, Sanders SJ, Blake E, Elkhateeb N, Gandhi A, Liang NSY, Morgan JT, Verwillow A, Verheijen J, Giles A, Williams S, Chopra M, Croft L, Dafsari HS, Davidson AE, Friedman J, Gregor A, Haque B, Lechner R, Montgomery KA, Ryten M, Schober E, Siegel G, Sullivan PJ, Whittle EF, Zardetto B, Yu TW, Synofzik M, Aartsma-Rus A, Costain G, Lauffer MC. Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments. Am J Hum Genet. 2025 May 01; 112(5):975-983.
-
Voss DM, Kral AJ, Sim G, Utama R, Lin KT, Cizmeciyan C, Schafer B, Cunniff PJ, Vakoc CR, Caruthers MH, Mishra L, Krainer AR. PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma. J Biol Chem. 2025 Apr; 301(4):108345.
-
McCaleb ML, Hughes SG, Grossman TR, Frazer-Abel A, Jung B, Yin L, Henry SP, Monia BP, Schneider E, Geary R, Brice GT. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 03; 230(2):152876.
-
Mejzini R, Caruthers MH, Schafer B, Kostov O, Sudheendran K, Ciba M, Danielsen M, Wilton S, Akkari PA, Flynn LL. Allele-Selective Thiomorpholino Antisense Oligonucleotides as a Therapeutic Approach for Fused-in-Sarcoma Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2024 Aug 03; 25(15).
-
Wan L, Kral AJ, Voss D, Sch?fer B, Sudheendran K, Danielsen M, Caruthers MH, Krainer AR. Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. Nucleic Acid Ther. 2024 08; 34(4):188-198.
-
Clerici S, Podrini C, Stefanoni D, Distefano G, Cassina L, Steidl ME, Tronci L, Canu T, Chiaravalli M, Spies D, Bell TA, Costa AS, Esposito A, D'Alessandro A, Frezza C, Bachi A, Boletta A. Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression. EMBO Mol Med. 2024 Jun; 16(6):1379-1403.
-
Paul S, Caruthers MH. Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry. Molecules. 2023 Jul 13; 28(14).
-
Lightbourne M, Startzell M, Bruce KD, Brite B, Muniyappa R, Skarulis M, Shamburek R, Gharib AM, Ouwerkerk R, Walter M, Eckel RH, Brown RJ. Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. J Clin Lipidol. 2022 Nov-Dec; 16(6):850-862.
-
Le BT, Paul S, Jastrzebska K, Langer H, Caruthers MH, Veedu RN. Thiomorpholino oligonucleotides as a robust class of next generation platforms for alternate mRNA splicing. Proc Natl Acad Sci U S A. 2022 09 06; 119(36):e2207956119.
-
Li Y, Li J, Wang J, Lynch DR, Shen X, Corey DR, Parekh D, Bhat B, Woo C, Cherry JJ, Napierala JS, Napierala M. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 2021 11 18; 49(20):11560-11574.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|